Eculizumab (sold under the brand name Soliris) is a humanized monoclonal antibody used to treat two rare and life-threatening diseases called paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). It works by blocking a protein called C5, which is part of the body’s immune system and helps to fight infection. Eculizumab is given as an intravenous (IV) infusion and is usually taken once every two weeks. It is the only treatment approved by the FDA for these two conditions.
Eculizumab, sold under the brand name Soliris, is a medication used to treat several specific conditions:
- Paroxysmal Nocturnal Hemoglobinuria (PNH): This is a rare blood disorder where red blood cells are destroyed by the immune system. Eculizumab helps by blocking this destructive process, reducing the breakdown of red blood cells and improving symptoms like fatigue and shortness of breath.
- Atypical Hemolytic Uremic Syndrome (aHUS): This is a serious blood clotting disorder that can damage the kidneys and other organs. Eculizumab helps prevent these blood clots from forming by targeting a specific protein in the immune system.
- Generalized Myasthenia Gravis: This is an autoimmune disease that weakens muscles. Eculizumab works by blocking a protein involved in the abnormal immune response that attacks muscle function.
- Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults: This is a rare autoimmune disease affecting the central nervous system, particularly the optic nerves and spinal cord. Eculizumab helps by targeting a specific protein involved in the inflammation process.
How it Works:
Eculizumab is a monoclonal antibody, a lab-made protein designed to target a specific molecule in the body. In this case, it binds to a protein called complement C5, which plays a role in the immune system's activation. By blocking C5, eculizumab prevents a chain reaction of events that can damage red blood cells and tissues in the various conditions it treats.
Important Considerations:
- Eculizumab is a powerful medication and should only be used under the supervision of a doctor specializing in the specific condition being treated.
- It is administered through intravenous (IV) infusion, typically at regular intervals.
- Eculizumab can increase the risk of serious infections, particularly meningococcal meningitis. Vaccination against meningococcus is crucial before starting treatment.
- There can be side effects, though typically mild, such as headache, fatigue, and nausea.
Disclaimer:
This information is intended for general knowledge and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.